GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CNBX Pharmaceuticals Inc (OTCPK:CNBX) » Definitions » Operating Margin %

CNBX Pharmaceuticals (CNBX Pharmaceuticals) Operating Margin % : -502.44% (As of Feb. 2024)


View and export this data going back to 2007. Start your Free Trial

What is CNBX Pharmaceuticals Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. CNBX Pharmaceuticals's Operating Income for the three months ended in Feb. 2024 was $-0.21 Mil. CNBX Pharmaceuticals's Revenue for the three months ended in Feb. 2024 was $0.04 Mil. Therefore, CNBX Pharmaceuticals's Operating Margin % for the quarter that ended in Feb. 2024 was -502.44%.

The historical rank and industry rank for CNBX Pharmaceuticals's Operating Margin % or its related term are showing as below:

CNBX' s Operating Margin % Range Over the Past 10 Years
Min: -43471.43   Med: -30900   Max: -131.85
Current: -131.85


CNBX's Operating Margin % is ranked better than
52.23% of 1032 companies
in the Biotechnology industry
Industry Median: -172.8 vs CNBX: -131.85

CNBX Pharmaceuticals's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

CNBX Pharmaceuticals's Operating Income for the three months ended in Feb. 2024 was $-0.21 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Feb. 2024 was $-0.71 Mil.

Warning Sign:

CNBX Pharmaceuticals Inc has never been profitable in the past 3 years. It lost money every year.


CNBX Pharmaceuticals Operating Margin % Historical Data

The historical data trend for CNBX Pharmaceuticals's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CNBX Pharmaceuticals Operating Margin % Chart

CNBX Pharmaceuticals Annual Data
Trend Aug14 Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -33,040.00 -43,471.43 - -9,846.67 -227.07

CNBX Pharmaceuticals Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -55.81 -161.00 -193.26 -502.44

Competitive Comparison of CNBX Pharmaceuticals's Operating Margin %

For the Biotechnology subindustry, CNBX Pharmaceuticals's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CNBX Pharmaceuticals's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CNBX Pharmaceuticals's Operating Margin % distribution charts can be found below:

* The bar in red indicates where CNBX Pharmaceuticals's Operating Margin % falls into.



CNBX Pharmaceuticals Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

CNBX Pharmaceuticals's Operating Margin % for the fiscal year that ended in Aug. 2023 is calculated as

Operating Margin %=Operating Income (A: Aug. 2023 ) / Revenue (A: Aug. 2023 )
=-0.931 / 0.41
=-227.07 %

CNBX Pharmaceuticals's Operating Margin % for the quarter that ended in Feb. 2024 is calculated as

Operating Margin %=Operating Income (Q: Feb. 2024 ) / Revenue (Q: Feb. 2024 )
=-0.206 / 0.041
=-502.44 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CNBX Pharmaceuticals  (OTCPK:CNBX) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


CNBX Pharmaceuticals Operating Margin % Related Terms

Thank you for viewing the detailed overview of CNBX Pharmaceuticals's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


CNBX Pharmaceuticals (CNBX Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
No. 3 Bethesda Metro Center, Suite 700, Bethesda, MD, USA, 20814
CNBX Pharmaceuticals Inc is a biotechnology company. It develops pharmaceuticals focusing on cancer research utilizing HTS technology and personalized bioinformatics tools. The company's main focus is the development of cannabinoid therapies and other technologies for the treatment of cancer, mainly cancers of the gastrointestinal tract, skin, breast, and prostate. The firm's main product is the RCC-33, an oral capsule for the treatment of colorectal cancer. The company tools include delivery systems, personalized medicine diagnostics, and therapies based on Cannabinoid compounds.
Executives
Cannabics Inc. 10 percent owner 108 WEST 13TH ST., WILMINGTON DE 19801
Thomas E Mills director, officer: President, CEO, CFO
North American Mining Corp 10 percent owner 6767 WEST TROPICANA AVENUE, SUITE 229, LAS VEGAS NV 89103
Lou Hilford director, officer: Vice-President, Secretary